Better diagnostics, the means to treat earlier stage-disease, disease-modifying therapies, and disease prevention
are the holy grails of autoimmune and infl ammatory disease drug development. However, basic science and
redundant biological pathways are holding back this therapy area. In this report, we investigate the autoimmune
and infl ammatory disease industry. We analyze 200 deals in this therapy area for 2007, 2008, and the fi rst fi ve
months of 2009. We assess what types of deals companies are executing and what business strategies they are
deploying for future success. We discuss recent industry-shaping events, industry drivers, and barriers that are
holding back this therapy area.
Questions Answered in This Report
Analyzing deals opens up a window to a company’s business strategies. What do the 200 deals related to autoimmune and infl ammatory diseases that took place in 2007, 2008, and the fi rst fi ve months of 2009 indicate about the business strategies of Big Biotech, Mid-Size Pharma, and Big Pharma? What technologies
are hot? What new targets were licensed or optioned?
Three mega-mergers were announced in early 2009. What impact will these deals have on this therapy area? Why did Pfi zer CEO Jeffrey Kindler think that Wyeth was the right answer for Pfi zer? What trouble might Merck & Co. have with the Schering-Plough acquisition? What might prevent Roche from achieving its goals in its acquisition of Genentech?
The number of generics and branded generics is rising in some segments of this therapy area. Which diseases are seeing an increase in these types of agents and why? What do GlaxoSmithKline’s recent deals with Aspen Pharmacare and Dr Reddy’s Laboratories indicate about this company’s current strategies?
Scope
Therapy area: Diseases; market size, top 25 companies by worldwide sales, major brands.
200 deals: Total deal volume; biobucks; 20 largest deals; Big Biotech, Mid-Size Pharma and Big
Pharma deals; most active disease areas; most active companies; top fi ve deals by technology, outlicensing,
divesting, new targets, biological pathways; nucleic acid therapeutics; budesonide deals;
reformulations; inhaler issues; combination products.
benefi ts of a portfolio of modest products, milestone-driven dealmaking, shared development
risk, emerging markets, generics markets, branded generics, life-cycle management, optimizing the
commercialization of off-patent drugs, a passion for biologics, drug recycling and reformulations,
fi xed-dose combinations.
Industry-shaping events: Big Pharma consolidation, market entry, safety issues, change of ownership
(0 items)
